SelectPSMA
Personalized Treatment Predictions
AI-powered predictions of patient outcomes following treatment with PSMA-targeted radiopharmaceuticals, helping to avoid ineffective treatments and side effects.

Personalized Treatment Predictions for Prostate Cancer
SelectPSMA utilizes cutting-edge AI technology to predict patient outcomes following treatment with PSMA-targeted radiopharmaceuticals.
Clinical Value
Enables improved patient selecton for 177Lu-PSMA-617 therapy and avoid futile treatments to improve patient outcome.
Benefits
Patients unlikely to benefit from Pluvicto therapy are directed towards more efficacious treatments for prostate cancer.

Applications of SelectPSMA
Explore how SelectPSMA enhances prostate cancer treatment across various settings.
Patient Selection
Identifies patients who are unlikely to benefit from treatment with 177Lu-PSMA-617.
Minimize Toxicity
Avoid futile treatments and unnecessary treatment-related side effects.
Medical Oncology
Assists medical oncologists to determine most efficacious treatment option for each individual patient.
Decision Support
Provides robust and reproducible data to support clinical decisions and improve healthcare resource allocation.
Patient Counseling
Aids in communicating to patients the likelihood of therapeutic response, helping them make informed decisions.